KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Temocillin versus meropenem for the targeted treatment of bacteraemia due to third-generation cephalosporin-resistant Enterobacterales (ASTARTÉ): protocol for a randomised, pragmatic trial.

Alicia Marín-Candón, Clara M Rosso-Fernández, Natalia Bustos de Godoy, Lorena López-Cerero, Belén Gutiérrez-Gutiérrez, Luis Eduardo López-Cortés, Lydia Barrera Pulido, Irene Borreguero Borreguero, María José León, Vicente Merino, Manuel Camean-Fernández, Pilar Retamar, Elena Salamanca, Alvaro Pascual, Jesús Rodriguez-Baño, ASTARTÉ Study Group

BMJ Open 11(9) e049481

PMID34580096
PMCIDPMC8477313
DOI10.1136/bmjopen-2021-049481
发表日期2021-09-28
摘要

摘要

INTRODUCTION: Alternatives to carbapenems are needed in the treatment of third-generation cephalosporin-resistant Enterobacterales (3GCR-E). Temocillin is a suitable candidate, but comparative randomised studies are lacking. The objective is to investigate if temocillin is non-inferior to carbapenems in the targeted treatment of bacteraemia due to 3GCR-E. METHODS AND ANALYSIS: Multicentre, open-label, randomised, controlled, pragmatic phase 3 trial. Patients with bacteraemia due to 3GCR-E will be randomised to receive intravenously temocillin (2 g three times a day) or carbapenem (meropenem 1 g three times a day or ertapenem 1 g once daily). The primary endpoint will be clinical success 7-10 days after end of treatment with no recurrence or death at day 28. Adverse events will be collected; serum levels of temocillin will be investigated in a subset of patients. For a 10% non-inferiority margin, 334 patients will be included (167 in each study arm). For the primary analysis, the absolute difference with one-sided 95% CI in the proportion of patients reaching the primary endpoint will be compared in the modified intention-to-treat population. ETHICS AND DISSEMINATION: The study started after approval of the Spanish Regulatory Agency and the reference institutional review board. Data will be published in peer-reviewed journals. TRIAL REGISTRATION NUMBER: NCT04478721.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。